Those who succeed in 2026 will be the organizations that set a bold vision, empower cross-functional collaboration, and stay committed to continuous innovation. The future of life sciences is one of extraordinary promise – and the recalibration underway today is setting the foundation for a healthier world tomorrow.
Drs. Rotem Gura-Sadovsky and Maayan Eilon-Ashkenazy explore the potential for AI to transform drug discovery, charting a path towards more targeted precision therapeutics.
This article answers the question: what if, instead of relying on systemic delivery, we could create a platform that anchors drugs directly at the site of need and controls its release over weeks or months?
Thanks to the pioneering work of researchers advancing our knowledge of basic science and cancer, the field has been able to transform the lives of millions of patients with CML. But challenges remain, and everyone in the industry strives to improve upon the “miracle drug” imatinib, that was approved almost 25 years ago.
William Sanders, PhD, explores the real-world challenges of scaling chromatography and highlights how contract development and manufacturing organizations (CDMOs) can help partners overcome them.
Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.
Anders Johansson, PhD, Polla Rouf, PhD, and Joel Hellrup, PhD, review an innovative drug delivery system that uses nanometer-thin, inorganic coatings to turn short-acting drugs into long-acting injectables.
John Tomtishen says amid shifting FDA priorities as well as developing geopolitical considerations, US companies are entering a new regulatory era, one that will define how CGTs are scaled, distributed, and delivered domestically.
COMPANY PROFILE
Sharp is a leading global provider of commercial packaging, clinical supply services and sterile manufacturing solutions for the pharmaceutical and biotechnology industries. For over 70 years, we have partnered with clients across every phase of the drug development journey — from early-phase clinical trials through to commercial launch and lifecycle management. Our mission is to support our clients in delivering life-changing therapies safely, efficiently and compliantly to patients worldwide. Click here for more.
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.
SGS, the world’s leading testing, inspection and certification company, recently announced the release of a new white paper, 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing.
Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological …
The biopharmaceutical classification system classifies drugs according to their permeability and solubility. Drugs with poor solubility and/or permeability are class II or IV type drugs, and these require special formulation technologies for solubility enhancement. In the past 25 …
Intradermal delivery has long been a critical method in medical and pharmaceutical fields, offering unique advantages for diagnosis, vaccination and therapeutic applications. This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as …
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
January 14 – Excipients
January 21 – Drug Delivery